Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
PARP inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2014 |
| gptkbp:ATCCode |
gptkb:L01XX43
|
| gptkbp:CASNumber |
763113-22-0
|
| gptkbp:chemicalFormula |
C24H23FN4O3
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:hasPatent |
US20070254935A1
|
| https://www.w3.org/2000/01/rdf-schema#label |
AZD2281
|
| gptkbp:indication |
BRCA-mutated cancers
|
| gptkbp:marketedAs |
gptkb:Lynparza
|
| gptkbp:mechanismOfAction |
inhibits PARP enzymes
|
| gptkbp:molecularWeight |
434.46 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea vomiting diarrhea fatigue decreased appetite |
| gptkbp:synonym |
gptkb:Olaparib
|
| gptkbp:target |
gptkb:PARP1
gptkb:PARP2 |
| gptkbp:UNII |
3KX376GY7L
|
| gptkbp:usedFor |
gptkb:cancer
pancreatic cancer prostate cancer |
| gptkbp:bfsParent |
gptkb:olaparib
|
| gptkbp:bfsLayer |
6
|